Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2023 Sep;58(9):2600-2609.
doi: 10.1002/ppul.26562. Epub 2023 Jun 21.

Changes in glucose tolerance in people with cystic fibrosis after initiation of first-generation CFTR modulator treatment

Rikke Spragge Ekblond  1 , Bibi Uhre Nielsen  1 , Christine Højte  1 , Thomas Peter Almdal  2 , James Shaw  3 , Tacjana Pressler  1 , Daniel Faurholt-Jepsen  1 , Inger Hee Mabuza Mathiesen  1
Affiliations
Observational Study

Changes in glucose tolerance in people with cystic fibrosis after initiation of first-generation CFTR modulator treatment

Rikke Spragge Ekblond et al. Pediatr Pulmonol. 2023 Sep.

Abstract

Background: Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have been shown to have a beneficial effect on pulmonary function and nutritional status in patients with cystic fibrosis (CF), but the extent to which they affect glucose tolerance is not fully understood. In the current study, we evaluated the change in glucose tolerance and insulin secretion after first-generation CFTR modulator treatment in adults with CF.

Methods: We performed a longitudinal observational study with an oral glucose tolerance test performed at baseline and after three and a half years of follow-up. The test comprised glucose, C-peptide and insulin measured at fasting, 1 h, and 2 h, and HbA1c at fasting. We compared changes in parameters of glucose tolerance and insulin secretion from baseline to follow-up.

Results: Among 55 participants, 37 (67%) were treated with a first-generation CFTR modulator for a median of 21 months. Glucose levels were unchanged in both the treated and untreated group. In the treated group, C-peptide levels declined, yet no significant differences in glucose, insulin, and C-peptide levels were observed between the groups. HbA1c increased in both groups, while no significant change in the insulin sensitivity indices was detected in either group. However, homeostatic model assessment for insulin resistance tended to decline in the treated group, whilst tending towards an increase in the untreated group. The difference between the groups reached statistical significance (p = 0.040).

Conclusion: Treatment with first-generation CFTR modulators, mainly tezacaftor/ivacaftor, did not seem to be associated with glucose tolerance nor insulin secretion in adults with CF. However, CFTR modulators may still have a beneficial effect on insulin sensitivity.

Keywords: CFTR modulator; Cystic fibrosis; cystic fibrosis-related diabetes; glucose tolerance; insulin secretion; oral glucose tolerance test.

PubMed Disclaimer

References

REFERENCES

    1. Heijerman H. Infection and inflammation in cystic fibrosis: a short review. J Cystic Fibrosis. 2005;4:3-5. doi:10.1016/j.jcf.2005.05.005
    1. Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W. Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care. 2009;32:1626-1631. doi:10.2337/dc09-0586
    1. Finkelstein SM, Wielinski CL, Elliott GR, et al. Diabetes mellitus associated with cystic fibrosis. J Pediatr. 1988;112:373-377. doi:10.1016/S0022-3476(88)80315-9
    1. Kelly A, Moran A. Update on cystic fibrosis-related diabetes. J Cystic Fibrosis. 2013;12:318-331. doi:10.1016/j.jcf.2013.02.008
    1. Coderre L, Debieche L, Plourde J, Rabasa-Lhoret R, Lesage S. The potential causes of cystic fibrosis-related diabetes. Front Endocrinol. 2021;12:702823. doi:10.3389/fendo.2021.702823

Publication types